Beam Therapeutics Inc (BEAM) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $28.92
• Market Cap: $3.00B
• EPS: $-4.05
• 52-Week High: $36.44
• 52-Week Low: $13.53

Market Sentiment

Beam Therapeutics Inc currently has a Bullish sentiment score of 0.33.

About Beam Therapeutics Inc

Beam Therapeutics Inc. is an innovative biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic therapies for patients with serious and often life-threatening diseases. By utilizing advanced gene-editing technologies, particularly base editing, Beam aims to create targeted treatments that address the root causes of genetic disorders. The company's robust pipeline showcases its commitment to transforming patient outcomes through precision medicine, posi...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Beam Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does BEAM pay dividends?

Beam Therapeutics Inc (BEAM) does not currently pay a regular dividend.

What is BEAM's market cap?

Beam Therapeutics Inc (BEAM) has a market capitalization of $3.00B with a current stock price of $28.92.